Immunotherapy Advances in Cancer Treatment: Harnessing the Immune System

Advances in immunotherapy are changing how we treat many cancers. These treatments help the body’s own immune system find and attack tumor cells, often with fewer long‑term side effects than traditional chemotherapy. This matters to people living with cancer now, survivors at risk of relapse, and families making decisions with their care teams. Because new options and safety steps are emerging rapidly, timely, reliable information can help you ask the right questions and get care that fits your needs.

What Is Immunotherapy and How It Works

Immunotherapy is a group of treatments that boost or guide the body’s defenses to fight cancer. The immune system can recognize cancer as “abnormal,” but tumors often hide. Immunotherapy works by removing those shields or by supercharging immune cells to attack.

The most widely used immunotherapies are immune checkpoint inhibitors. These drugs block “brakes” on immune cells, such as PD‑1/PD‑L1 and CTLA‑4, so T cells can recognize and kill cancer cells. Examples include pembrolizumab, nivolumab, cemiplimab (PD‑1), atezolizumab, durvalumab, avelumab (PD‑L1), and ipilimumab (CTLA‑4). Newer targets like LAG‑3 (e.g., relatlimab with nivolumab) add options for some cancers.

Another approach is adoptive cell therapy. Doctors collect a patient’s immune cells, grow or engineer them in a lab, and give them back. CAR‑T cells are engineered to recognize specific proteins such as CD19 (many B‑cell leukemias/lymphomas) or BCMA (multiple myeloma). Tumor‑infiltrating lymphocyte (TIL) therapy expands a patient’s own tumor‑fighting T cells; in 2024, the FDA approved the first TIL therapy for advanced melanoma.

Oncolytic virus therapy uses a modified virus that infects and kills cancer cells and sparks an immune attack. T‑VEC (talimogene laherparepvec) is approved for certain melanomas and is injected into tumors.

Cancer vaccines train the immune system to recognize tumor markers. Preventive vaccines like HPV and hepatitis B vaccines lower the risk of virus‑related cancers. Therapeutic vaccines, including personalized mRNA vaccines paired with checkpoint drugs, are in advanced clinical trials for melanoma and other cancers.

Bispecific antibodies (for example, blinatumomab for some leukemias and teclistamab for multiple myeloma) act like a bridge, linking T cells to cancer cells to trigger killing. Other immune‑modulating drugs and cytokines are being refined to improve precision and reduce side effects.

Signs and Symptoms: Cancer and Immune Response Signals

Cancer symptoms vary by organ but often include warning signs of uncontrolled cell growth. Symptoms can be subtle at first and may overlap with common illnesses, so staying alert matters.

Common cancer symptoms may include:

Unexplained weight loss, fever, or night sweats
Lasting fatigue or weakness
Pain that does not go away
Lumps, swelling, or new skin changes (sores, dark streaks, changing moles)
Persistent cough or hoarseness; blood in sputum, urine, or stool
Trouble swallowing, ongoing belly changes (diarrhea/constipation), or abnormal bleeding

The immune system also gives clues. When it is activated against tumors, people may notice temporary inflammation such as mild fevers, achy joints, or swelling near tumors. On scans, some patients treated with immunotherapy show “pseudoprogression,” where tumors look larger before they shrink, due to immune cells crowding in.

Some syndromes are caused by immune cross‑reactions to tumor proteins (paraneoplastic syndromes). These can affect the nervous system, hormones, skin, or blood. Examples include muscle weakness, rashes, or low sodium from abnormal hormone signals.

Blood tests may show anemia, abnormal liver enzymes, high calcium, or increased LDH—signals that can reflect tumor burden or inflammation. These are not specific to cancer but help your care team track changes over time.

If you are already on immunotherapy, new symptoms can reflect treatment benefit, normal inflammation, or side effects. Always report changes early so your team can sort out the cause and adjust care quickly.

Why Cancer Develops and How Immunotherapy Addresses It

Cancer begins when DNA damage builds up and cells grow without control. Over time, these cells learn to spread and resist normal death signals. The process is driven by gene changes, environmental exposures, chronic inflammation, and chance.

The immune system constantly patrols for abnormal cells. This balance is called “cancer immunoediting”: elimination (immune cells kill abnormal cells), equilibrium (dormant balance), and escape (tumors evolve ways to hide). Escape happens through loss of tumor antigens, reduced MHC presentation, release of suppressive chemicals, and expression of checkpoint molecules like PD‑L1.

Checkpoint inhibitors reverse some of these escape tactics by lifting brakes on T cells. Once re‑activated, T cells can recognize antigens on cancer cells and deliver precise killing. This can lead to durable remissions in some cancers because the immune system “remembers” tumor markers.

Adoptive cell therapies overcome low natural T‑cell numbers or weak recognition by giving patients large armies of potent cells. CAR‑T cells bypass MHC presentation and directly target surface proteins, which is why they can work even when tumors downregulate antigen presentation.

Oncolytic viruses and intratumoral treatments inflame “cold” tumors that lack immune cell entry. By releasing danger signals and new antigens, they can convert tumors into “hot” targets that respond better to systemic immunotherapy.

Combinations—such as immunotherapy plus radiation or targeted drugs—aim to attack cancer from several angles at once. Radiation, for example, can release tumor antigens (“in situ vaccine” effect), which may enhance checkpoint inhibitor responses.

Risk Factors for Cancer and for Immunotherapy Response

Cancer risk increases with age and depends on exposures and genetics. While risk does not equal destiny, understanding your profile helps tailor screening and prevention.

Major cancer risk factors include tobacco use, heavy alcohol use, obesity, physical inactivity, diets low in fruits/vegetables, chronic infections (HPV, hepatitis B/C, H. pylori), ultraviolet and ionizing radiation, certain chemicals (e.g., asbestos), and air pollution. Family history and inherited syndromes (e.g., BRCA, Lynch) also raise risk.

Tumors vary in how “visible” they are to the immune system. Features linked to better checkpoint inhibitor responses include high PD‑L1 expression, MSI‑H/dMMR status, and high tumor mutational burden (TMB). Some virus‑related cancers (e.g., HPV‑positive head and neck cancers) can also respond well due to distinct antigens.

Factors linked to weaker responses include “cold” tumors with few T cells, very low TMB, heavy use of immunosuppressive drugs, poor performance status, and rapid disease progression. Certain antibiotics given right before or soon after starting immunotherapy may alter the gut microbiome and reduce benefit.

The gut microbiome can influence response and toxicity. Diet quality, recent antibiotics, and probiotics can shift the microbiome. Do not self‑start supplements for “immune boosting”; discuss with your care team first.

For CAR‑T and bispecific antibodies, response depends on the presence of the target (such as CD19 or BCMA) and the overall health of the immune system. Prior therapies, bone marrow reserve, and infection risk also matter when planning these treatments.

Diagnosis and Staging: Evaluations Before Starting Treatment

Diagnosing cancer starts with a tissue sample. A biopsy confirms cancer type and grade. A pathologist reviews markers on tumor cells to guide treatment choices.

Staging determines how far cancer has spread. Imaging may include CT, MRI, PET/CT, or ultrasound. Accurate staging helps decide if immunotherapy should be given before surgery (neoadjuvant), after surgery (adjuvant), or for advanced disease.

Molecular and immune testing refine choices. Tests may include PD‑L1 staining, MSI/dMMR status, TMB, and next‑generation sequencing for gene changes. Virus testing (e.g., HPV in some head and neck cancers, EBV in certain lymphomas) can also guide care.

Baseline labs assess readiness and safety. These often include a complete blood count, kidney and liver tests, thyroid function tests (TSH, T4), blood sugar, and pregnancy testing when relevant. For CAR‑T and TIL therapy, infection screening (hepatitis B/C, HIV), immunoglobulin levels, and vaccination review are standard.

Your care team will also review other health issues, medications, and goals. This includes heart and lung history, prior autoimmune disease, organ transplants, and the need for steroids or blood thinners. These factors can affect risks and benefits of immunotherapy.

Planning may include fertility counseling, central line placement (for cell therapies), timing of vaccines (avoid live vaccines around intensive immune therapies), and supportive care plans. Enrollment in a clinical trial may offer access to cutting‑edge options and extra monitoring.

Treatment Options: Latest Immunotherapy Advances and Combinations

Immunotherapy is used alone or in combination with other treatments. Choices depend on cancer type, stage, biomarkers, prior therapies, and your health goals.

Common immunotherapy options include:

Checkpoint inhibitors: PD‑1/PD‑L1 and CTLA‑4 agents; newer LAG‑3 combinations (e.g., nivolumab + relatlimab in melanoma)
Adoptive cell therapies: CAR‑T for several B‑cell cancers and multiple myeloma; TIL therapy for advanced melanoma
Bispecific antibodies: examples include blinatumomab (CD19/CD3) in some leukemias, teclistamab (BCMA/CD3) and other agents in myeloma, and CD20/CD3 drugs in some lymphomas
Oncolytic virus therapy: T‑VEC for injectable melanoma lesions
Cancer vaccines: preventive HPV and hepatitis B vaccines; therapeutic vaccines in clinical trials (including personalized mRNA vaccines)

Checkpoint inhibitors have moved earlier in care for several cancers. Examples include adjuvant therapy for melanoma and bladder cancer, and neoadjuvant plus adjuvant approaches for lung cancer. In liver cancer, combining immunotherapy with targeted anti‑angiogenic therapy (e.g., atezolizumab plus bevacizumab) improves survival in many patients.

In kidney cancer, combining immunotherapy with targeted drugs (e.g., pembrolizumab plus axitinib) or using dual‑immunotherapy (nivolumab plus ipilimumab) can increase response rates. In triple‑negative breast cancer, pembrolizumab plus chemotherapy helps some patients with PD‑L1 positive tumors, including in early‑stage high‑risk disease.

For colorectal and endometrial cancers with MSI‑H/dMMR, checkpoint inhibitors such as pembrolizumab or dostarlimab can be highly effective. Pembrolizumab also has a tumor‑agnostic approval for TMB‑high tumors after other therapies.

Radiation and immunotherapy can work together. Radiation can release tumor antigens and increase immune cell entry, sometimes aiding systemic responses. Trials continue to test optimal timing and dosing.

Clinical trials test next‑generation checkpoints (e.g., TIGIT inhibitors under study), cytokine variants, intratumoral agents, and novel cell therapies. Ask your team if a trial fits your cancer type and goals.

Prevention and Lifestyle: Lowering Cancer Risk and Supporting Treatment

Lifestyle changes cannot guarantee cancer prevention, but they lower risk and improve treatment tolerance. They also support the immune system’s ability to work with immunotherapy.

Key health tips:

Do not smoke or vape; avoid secondhand smoke
Limit alcohol (ideally no more than 1 drink/day for women, 2 for men; less is better)
Aim for a healthy weight; move your body most days (150 minutes/week of moderate activity if you can)
Eat a plant‑forward diet rich in vegetables, fruits, whole grains, beans, nuts, and fish; limit processed meats and sugary drinks
Protect your skin from UV radiation (shade, clothing, broad‑spectrum SPF 30+)
Stay up to date with cancer screenings and vaccinations (HPV, hepatitis B, influenza, COVID‑19 as recommended)

During immunotherapy, tell your team about all supplements and over‑the‑counter drugs. Some herbal products can interact with treatments or steroids used for side effects. Do not start “immune boosters” without medical advice.

Support gut health with a balanced, fiber‑rich diet rather than high‑dose commercial probiotics unless your clinician recommends them. The gut microbiome influences immunotherapy outcomes, and diet is a safer way to support it.

Prevent infections by practicing hand hygiene, safe food handling, and avoiding sick contacts when your counts are low. Most inactivated vaccines are safe during checkpoint therapy; live vaccines should be avoided around CAR‑T, TIL therapy, and during intensive immunosuppression—ask your team.

Manage stress, sleep, and social support. Counseling, peer groups, and gentle mind‑body practices (breathing, yoga, mindfulness) can improve quality of life and help you stick with treatment.

Keep a symptom diary. Note rashes, diarrhea, breathing changes, headaches, vision issues, or mood/cognitive changes. Early reporting can prevent mild problems from becoming emergencies.

Complications and Immune-Related Adverse Events

Checkpoint inhibitors can cause immune‑related adverse events (irAEs)—inflammation of normal organs as the immune system becomes more active. Most are manageable if caught early.

Common irAEs include skin rashes and itching; diarrhea or colitis; liver inflammation (hepatitis); thyroid problems (hypo‑ or hyperthyroidism); and lung inflammation (pneumonitis). Less common but serious events include hypophysitis (pituitary inflammation), adrenal insufficiency, type 1 diabetes, kidney inflammation (nephritis), heart inflammation (myocarditis), and nerve problems.

Management usually follows standard guidelines (e.g., CTCAE grading). Mild events may improve with monitoring or creams. Moderate to severe irAEs often require holding immunotherapy and starting corticosteroids. Some cases need other immune‑suppressing drugs (e.g., infliximab for severe colitis, mycophenolate for hepatitis).

CAR‑T and some bispecific antibodies can cause cytokine release syndrome (CRS)—fever, low blood pressure, low oxygen—and ICANS (neurologic toxicity) with confusion, tremor, or seizures. These events are treatable with supportive care, tocilizumab, and steroids when needed, usually in hospitals experienced with these therapies.

TIL therapy requires lymphodepleting chemotherapy and often IL‑2, which can cause low blood counts, infections, fluid shifts, and organ stress. Care teams monitor closely and give supportive treatments until patients recover.

Some endocrine irAEs (like hypothyroidism) can be long‑lasting and may require lifelong hormone replacement. Keep wearing a medical alert bracelet if you have adrenal insufficiency, and carry an emergency steroid plan.

When to Seek Medical Help or Urgent Care

Know when to call your oncology team versus when to go to urgent care or the emergency department. Early action can prevent serious harm.

Call your care team promptly for new or worsening symptoms, even if they seem mild. With immunotherapy, small changes can be early signs of inflammation that is easier to treat if caught quickly.

Seek urgent care or go to the emergency department immediately for:

Fever of 100.4°F (38°C) or higher, chills, or shaking
Shortness of breath, chest pain, new or worsening cough
Severe or persistent diarrhea (four or more extra stools/day), bloody or black stools, severe abdominal pain
Severe headache, confusion, weakness on one side, vision changes, fainting, or seizures
Yellowing of skin/eyes, dark urine, very low urine output, new irregular heartbeat, or severe rash/blistering

If you recently received CAR‑T or a bispecific antibody and develop high fever, confusion, tremors, or seizures, treat this as an emergency and tell responders you may have CRS/ICANS.

When you arrive, show your immunotherapy wallet card or treatment summary. ER teams should know that early steroids can be lifesaving in severe irAEs and do not “cancel” long‑term benefits when used appropriately.

If you are pregnant, might be pregnant, or are breastfeeding, tell your team immediately. Most immunotherapies are avoided during pregnancy due to unknown or potential risks to the fetus.

FAQ

What cancers benefit most from immunotherapy?
Many cancers benefit, including melanoma, lung cancer, kidney cancer, bladder cancer, some head and neck cancers, liver cancer, Hodgkin lymphoma, and certain colorectal and endometrial cancers with MSI‑H/dMMR. Blood cancers like leukemias, lymphomas, and multiple myeloma respond to CAR‑T or bispecifics.
How long does immunotherapy treatment last?
It varies by cancer type and drug—often 1 to 2 years for checkpoint inhibitors if disease is controlled. CAR‑T and TIL therapies are usually one‑time treatments with monitoring. Your plan depends on response, side effects, and goals.
Can immunotherapy be combined with chemotherapy or radiation?
Yes. In many cancers, immunotherapy is combined with chemotherapy, targeted therapy, or radiation to improve response. The best sequence and dose depend on tumor type and biomarkers.
What is pseudoprogression?
It is an early increase in tumor size on scans due to immune cell infiltration rather than true growth. It is uncommon but recognized with checkpoint inhibitors. Doctors use clinical signs, repeat imaging, and sometimes biopsy to tell the difference.
Are vaccines safe during immunotherapy?
Inactivated vaccines (like flu shots) are generally safe during checkpoint therapy. Live vaccines are avoided around CAR‑T/TIL therapy and in people receiving high‑dose steroids or other immunosuppression. Always check with your oncology team.
What if I have an autoimmune disease?
Some people with autoimmune conditions can still receive immunotherapy with careful monitoring, but the risk of flares is higher. Decisions are individualized.
How are costs handled?
Many immunotherapies are covered by insurance, but copays can be significant. Assistance programs, foundations, and clinical trials may help. Ask your care team’s financial counselor.

More Information

Mayo Clinic – Immunotherapy for cancer: https://www.mayoclinic.org/tests-procedures/immunotherapy-for-cancer
MedlinePlus – Cancer immunotherapy: https://medlineplus.gov/cancerimmunotherapy.html
CDC – HPV vaccination: https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html
WebMD – Immunotherapy side effects: https://www.webmd.com/cancer/immunotherapy-side-effects
Healthline – CAR-T therapy overview: https://www.healthline.com/health/cancer/car-t-cell-therapy

If this article helped you, share it with someone who may benefit. For personal guidance, talk with your oncology team or primary care provider. To explore related topics and find local resources, visit Weence.com.